Literature DB >> 27045133

Heterozygous Familial Hypercholesterolemia.

Angela Onorato1, Amy C Sturm2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27045133     DOI: 10.1161/CIRCULATIONAHA.115.020701

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  8 in total

1.  Familial Hypercholesterolemia in a Healthy Elderly Population.

Authors:  Paul Lacaze; Robert Sebra; Moeen Riaz; Amanda J Hooper; Jane Tiller; Andrew Bakshi; Robyn L Woods; Andrew M Tonkin; Christopher M Reid; Anne M Murray; Stephen J Nicholls; Gerald F Watts; Eric Schadt; John J McNeil
Journal:  Circ Genom Precis Med       Date:  2020-06-10

Review 2.  Genetics, Dyslipidemia, and Cardiovascular Disease: New Insights.

Authors:  Ricardo Stein; Filipe Ferrari; Fernando Scolari
Journal:  Curr Cardiol Rep       Date:  2019-06-21       Impact factor: 2.931

Review 3.  Cardiovascular Disease Prevention: Training Opportunities, the Challenges, and Future Directions.

Authors:  Anum Saeed; Kaustubh Dabhadkar; Salim S Virani; Peter H Jones; Christie M Ballantyne; Vijay Nambi
Journal:  Curr Atheroscler Rep       Date:  2018-05-21       Impact factor: 5.113

Review 4.  Exploring the Efficacy of Alirocumab and Evolocumab in Reducing Low-Density Lipoprotein (LDL) Cholesterol Levels in Patients With Familial Hypercholesterolemia: A Systematic Review.

Authors:  Gaurav Luthra; Mahrukh Shahbaz; Halah Almatooq; Paul Foucambert; Faith Esbrand; Sana Zafar; Venkatesh Panthangi; Adrienne R Cyril Kurupp; Anjumol Raju; Safeera Khan
Journal:  Cureus       Date:  2022-09-08

Review 5.  Women Living with Familial Hypercholesterolemia: Challenges and Considerations Surrounding Their Care.

Authors:  Sujana Balla; Eson P Ekpo; Katherine A Wilemon; Joshua W Knowles; Fatima Rodriguez
Journal:  Curr Atheroscler Rep       Date:  2020-08-20       Impact factor: 5.113

6.  A Systematic Review and Meta-Analysis of Therapeutic Efficacy and Safety of Alirocumab and Evolocumab on Familial Hypercholesterolemia.

Authors:  Xiaoyue Ge; Tiantian Zhu; Hao Zeng; Xin Yu; Juan Li; Shanshan Xie; Jinjin Wan; Huiyao Yang; Keke Huang; Weifang Zhang
Journal:  Biomed Res Int       Date:  2021-10-31       Impact factor: 3.411

7.  Familial hypercholesterolemia in very young myocardial infarction.

Authors:  Sha Li; Hui-Wen Zhang; Yuan-Lin Guo; Na-Qiong Wu; Cheng-Gang Zhu; Xi Zhao; Di Sun; Xiong-Yi Gao; Ying Gao; Yan Zhang; Ping Qing; Xiao-Lin Li; Jing Sun; Geng Liu; Qian Dong; Rui-Xia Xu; Chuan-Jue Cui; Jian-Jun Li
Journal:  Sci Rep       Date:  2018-06-11       Impact factor: 4.379

8.  Relations of physical signs to genotype, lipid and inflammatory markers, coronary stenosis or calcification, and outcomes in patients with heterozygous familial hypercholesterolemia.

Authors:  Ming-Ming Liu; Jia Peng; Yuan-Lin Guo; Cheng-Gang Zhu; Na-Qiong Wu; Rui-Xia Xu; Qian Dong; Jian-Jun Li
Journal:  J Transl Med       Date:  2021-12-07       Impact factor: 5.531

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.